Therapy Name | Bardoxolone methyl |
Therapy Description |
Bardoxolone methyl (CDDO-Me) is a derivative of a synthetic triterpenoid, 2-cyano-3,12-dioxooleana- 1,9-dien-28-oic acid (CDDO), which targets KEAP1, leading to the activation of NRF2. CDDO-Me also binds to IKK? and inhibits NF-?B activation. CDDO-Me is developed for the treatment of inflammation and cancer (PMID: 25364233) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bardoxolone methyl | CDDO-Me|RTA 402 | Bardoxolone methyl (CDDO-Me) is a derivative of a synthetic triterpenoid, 2-cyano-3,12-dioxooleana- 1,9-dien-28-oic acid (CDDO), which targets KEAP1, leading to the activation of NRF2. CDDO-Me also binds to IKK? and inhibits NF-?B activation. CDDO-Me is developed for the treatment of inflammation and cancer (PMID: 25364233) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Advanced Solid Tumor | not applicable | Bardoxolone methyl | Phase I | Actionable | In a Phase I trial, Bardoxolone methyl (CDDO-Me) was well tolerated by patients with advanced solid tumors, with a complete tumor response observed in a mantle cell lymphoma patient (PMID: 25364233). | 25364233 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|